Antibody slows Alzheimer's mental decline

• Autores: Andy Coghlan
• Localización: New scientist, ISSN 0262-4079, Nº. 3014, 2015, pág. 14
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • At last, a ray of hope for people with Alzheimer's disease. In a field where almost all clinical trials of new drugs fail, a drug called aducanumab appears to be bucking the trend. In a small trial, the drug slowed the progression of the disease and reduced deposits of amyloid plaques, the substances blamed for damaging the brains of people with Alzheimer's. This is the first time a drug has a statistically significant effect on both cognition and amyloid in people with mild disease, says Alfred Sandrock at Bioqen, the firm that developed aducanumab, based in Cambridge MA.